Health and Fitness Health and Fitness
Sun, February 20, 2011
Fri, February 18, 2011
Thu, February 17, 2011
Wed, February 16, 2011
Tue, February 15, 2011
Mon, February 14, 2011
Fri, February 11, 2011
Thu, February 10, 2011
Wed, February 9, 2011
Tue, February 8, 2011
Mon, February 7, 2011
[ Mon, Feb 07th 2011 ] - Market Wire
00 A.M. EST
Sun, February 6, 2011
Fri, February 4, 2011
Thu, February 3, 2011
Wed, February 2, 2011
Tue, February 1, 2011

Exelixis Announces February 22 Webcast of Its Fourth Quarter & Full Year 2010 Financial Results Conference Call


//health-fitness.news-articles.net/content/2011/ .. year-2010-financial-results-conference-call.html
Published in Health and Fitness on Thursday, February 10th 2011 at 3:22 GMT by Market Wire   Print publication without navigation


SOUTH SAN FRANCISCO, Calif.--([ BUSINESS WIRE ])--Exelixis, Inc. (NASDAQ: EXEL) will release its fourth quarter and full year 2010 financial results on Tuesday, February 22, 2011, after the markets close. The announcement will be followed by a live webcast at 5:00 p.m. EST/ 2:00 p.m. PST. During the webcast, Exelixis management will discuss the companya™s financial results, 2011 financial guidance, corporate strategy, recent clinical data and development plans and priorities for cabozantinib (XL184), and provide a general business update. The webcast may be accessed in the Event Calendar page under Investors at [ http://www.exelixis.com ].

An archived replay of the webcast will be available on the Event Calendar page under Investors at [ http://www.exelixis.com ] and via phone until 11:59 p.m. EST/8:59 p.m. PST on March 22, 2011. Access numbers for the phone replay are: 888-286-8010 (domestic) and 617-801-6888 (international); the passcode is 13557378.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer. The company is leveraging its biological expertise and integrated research and development capabilities to generate a pipeline of development compounds with significant therapeutic and commercial potential for the treatment of cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 3, phase 2, and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb Company, sanofi-aventis, GlaxoSmithKline, Genentech (a wholly owned member of the Roche Group), Boehringer Ingelheim, and Daiichi-Sankyo for several compounds in its pipeline. For more information, please visit the company's web site at [ www.exelixis.com ].


Publication Contributing Sources